Maxime Dely: What If Whole Blood Became the Standard Again in Massive Transfusion?
Maxime Dely, Therapeutic Solutions Sales Consultant at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“What if whole blood became the standard again in massive transfusion?
In the management of massive hemorrhage, current protocols are well established: alternating red blood cell concentrates, plasma, and platelets – a structured sequence designed to approximate whole blood.
But an important question is increasingly being raised:
Why not use leukoreduced whole blood directly?
The advantages are clear:
- A product that is inherently complete and balanced
- Simplified logistics (single storage condition and unified shelf-life considerations)
- More efficient inventory management
From a scientific standpoint, several recent studies indicate that whole blood offers efficacy comparable to component therapy, particularly regarding early survival and correction of coagulopathy.
Beyond clinical outcomes, this also prompts broader reflection on our organizational models.
And you – have your institutions already begun exploring this shift?”
Find more posts featuring Maxime Dely on Hemostasis Today.
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs